Our flow cytometry analysis in gliomas revealed two levels of expression of PD-L1 (herein defined as PD-L1_lo and PD-L1_hi) (Figure 3A), both in tumor (CD45−) and in immune (CD45+) cells. Here, PTPRC is linked to glioma.